Baseline characteristics
| Ovarian cancer patients (n=29) | Controls (n=32) | P value | |
| Age, years | 66 (32–83) | 57 (45–82) | 0.063 |
| Body mass index, kg/m2 | 25 (19–32) | 23 (20–44) | 0.644 |
| CA125, kIU/L | 360 (8–2196) | 20 (9–142) | <0.001 |
| Menopausal status | 0.321 | ||
| Pre-menopausal | 4 (14) | 8 (25) | |
| Post-menopausal | 25 (86) | 23 (72) | |
| Unknown | 0 | 1 (3) | |
| Histology | |||
| High-grade serous | 20 (69) | ||
| Endometrioid | 3 (10) | ||
| Clear cell | 1 (3) | ||
| Malignant mixed Müllerian tumor | 1 (3) | ||
| Mixed* | 4 (14) | ||
| Myoma | 9 (28) | ||
| Cystadenoma ovarii | 10 (31) | ||
| Fibroma/teratoma ovarii | 7 (22) | ||
| Other† | 6 (19) | ||
| FIGO stage | NA | ||
| IA | 1 (3) | ||
| IB | 0 | ||
| IC | 2 (7) | ||
| IIA | 2 (7) | ||
| IIB | 2 (7) | ||
| IIC | 0 | ||
| IIIA | 1 (3) | ||
| IIIB | 4 (14) | ||
| IIIC | 14 (48) | ||
| IV | 3 (10) |
Values presented as median (range) or N (%).
*Mixed histology included two clear cell/serous, one clear cell/endometrioid, and one serous/endometrioid.
†Other histology included one adenomyosis, one inflammation, two prolapse, and two normal.
CA125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics.